Skip to main content

Technivie Dosage

Generic name: RITONAVIR 50mg, OMBITASVIR HEMINONAHYDRATE 12.5mg, PARITAPREVIR DIHYDRATE 75mg
Dosage form: tablets
Drug class: Antiviral combinations

Medically reviewed by Drugs.com. Last updated on Dec 4, 2023.

Testing Prior to the Initiation of Therapy

  • Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with TECHNIVIE.
  • Prior to initiation of TECHNIVIE, assess hepatic laboratory and clinical evidence of hepatic decompensation. Prior to initiation of ribavirin, assess for underlying cardiac disease and refer to the ribavirin prescribing information.

Recommended Dosage in Adults

TECHNIVIE is ombitasvir, paritaprevir and ritonavir fixed dose combination tablets.

The recommended dosage of TECHNIVIE is two tablets taken orally once daily (in the morning). Take TECHNIVIE with a meal without regard to fat or calorie content.

TECHNIVIE is used in combination with ribavirin (RBV). When administered with TECHNIVIE, the recommended dosage of RBV is based on weight: 1000 mg per day for subjects less than 75 kg and 1200 mg per day for those weighing at least 75 kg, divided and administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information.

Table 1 shows the recommended TECHNIVIE treatment regimen and duration for HCV genotype 4 patients without cirrhosis or with compensated cirrhosis.

Table 1. Treatment Regimen and Duration for Patients with HCV Genotype 4 without Cirrhosis or with Compensated Cirrhosis
Patient Population Treatment Duration
Genotype 4 without cirrhosis or with
compensated cirrhosis (Child-Pugh A)
TECHNIVIE + ribavirin* 12 weeks
*TECHNIVIE administered without RBV for 12 weeks may be considered for treatment-naïve patients without cirrhosis who cannot take or tolerate ribavirin.

Dosage in Patients with Hepatic Impairment

TECHNIVIE is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B and C).

Frequently asked questions

More about Technivie (ombitasvir / paritaprevir / ritonavir)

Patient resources

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.